Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Acalabrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia; Infections
- Focus Proof of concept; Therapeutic Use
- Acronyms PreVent-ACaLL
Most Recent Events
- 15 Jun 2023 Results (n=118) clinically validating the predictive performance of CLL-TIM identifying newly diagnosed patients with high risk of infection and/or treatment as part of this study, presented at the 28th Congress of the European Haematology Association
- 10 Feb 2020 Status changed from not yet recruiting to recruiting.
- 06 Nov 2019 According to trial design released in 61st Annual Meeting and Exposition of the American Society of Hematology, first patient enrollment in trial was planned for September 2019 and primary outcome expected in 2021.